You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.
By comparing viruses in parts of China with or without endemic EBV-associated nasal cancers, researchers narrowed in on two viral variants associated with increased cancer risk.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
Quest, the largest private, independent medical laboratory in Singapore, will now be able to offer Lucence's menu of liquid biopsy tests to its patients.
The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.